Smith, Moore & Co. Abb Vie Inc. Transaction History

Smith, Moore & Co.

$1.03 Billion
Q3 2024

A detailed history of Smith, Moore & Co. transactions in Abb Vie Inc. stock. As of the latest transaction made, Smith, Moore & Co. holds 30,163 shares of ABBV stock, worth $5.3 Million. This represents 0.58% of its overall portfolio holdings.

Number of Shares

30,163

Previous 32,000 5.74%

Holding current value

$5.3 Million

Previous $5.49 Million 8.53%

% of portfolio

0.58%

Previous 0.57%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$163.84 - $199.33 $300,974 - $366,169	-1,837 Reduced 5.74%	30,163 $5.96 Million
Q2 2024 Aug 14, 2024	SELL	$154.79 - $180.76 $214,384 - $250,352	-1,385 Reduced 4.15%	32,000 $5.49 Million
Q1 2024 May 10, 2024	SELL	$159.82 - $182.1 $277,127 - $315,761	-1,734 Reduced 4.94%	33,385 $6.08 Million
Q4 2023 Feb 13, 2024	SELL	$137.6 - $154.97 $104,163 - $117,312	-757 Reduced 2.11%	35,119 $5.44 Million
Q3 2023 Nov 14, 2023	BUY	$133.59 - $154.65 $60,115 - $69,592	450 Added 1.27%	35,876 $5.35 Million
Q2 2023 Aug 11, 2023	SELL	$132.51 - $164.9 $80,036 - $99,599	-604 Reduced 1.68%	35,426 $4.77 Million
Q1 2023 May 12, 2023	SELL	$144.61 - $166.54 $272,445 - $313,761	-1,884 Reduced 4.97%	36,030 $5.74 Million
Q4 2022 Feb 13, 2023	SELL	$138.31 - $165.87 $71,091 - $85,257	-514 Reduced 1.34%	37,914 $6.13 Million
Q3 2022 Nov 14, 2022	SELL	$134.21 - $153.93 $166,823 - $191,334	-1,243 Reduced 3.13%	38,428 $5.16 Million
Q2 2022 Aug 12, 2022	SELL	$137.62 - $174.96 $114,086 - $145,041	-829 Reduced 2.05%	39,671 $6.08 Million
Q1 2022 May 12, 2022	SELL	$131.98 - $163.75 $117,330 - $145,573	-889 Reduced 2.15%	40,500 $6.57 Million
Q4 2021 Feb 08, 2022	BUY	$107.43 - $135.93 $95,827 - $121,249	892 Added 2.2%	41,389 $5.6 Million
Q3 2021 Nov 12, 2021	BUY	$106.4 - $120.78 $30,004 - $34,059	282 Added 0.7%	40,497 $4.37 Million
Q2 2021 Aug 10, 2021	BUY	$105.21 - $117.21 $221,887 - $247,195	2,109 Added 5.53%	40,215 $4.53 Million
Q1 2021 May 14, 2021	SELL	$102.3 - $112.62 $92,274 - $101,583	-902 Reduced 2.31%	38,106 $4.12 Million
Q4 2020 Feb 16, 2021	BUY	$80.49 - $108.67 $54,974 - $74,221	683 Added 1.78%	39,008 $4.18 Million
Q3 2020 Nov 12, 2020	BUY	$85.91 - $100.83 $192,352 - $225,758	2,239 Added 6.2%	38,325 $3.36 Million
Q2 2020 Aug 10, 2020	BUY	$73.37 - $98.18 $283,061 - $378,778	3,858 Added 11.97%	36,086 $3.54 Million
Q1 2020 May 15, 2020	SELL	$64.5 - $97.79 $24,316 - $36,866	-377 Reduced 1.16%	32,228 $2.46 Million
Q4 2019 Feb 07, 2020	BUY	$72.13 - $90.25 $115,552 - $144,580	1,602 Added 5.17%	32,605 $2.89 Million
Q3 2019 Nov 07, 2019	SELL	$62.98 - $75.72 $288,196 - $346,494	-4,576 Reduced 12.86%	31,003 $2.35 Million
Q2 2019 Aug 15, 2019	BUY	$65.7 - $83.98 $57,816 - $73,902	880 Added 2.54%	35,579 $2.59 Million
Q1 2019 May 07, 2019	BUY	$77.14 - $90.79 $210,746 - $248,038	2,732 Added 8.55%	34,699 $2.8 Million
Q4 2018 Feb 15, 2019	BUY	$77.85 - $96.01 $5,605 - $6,912	72 Added 0.23%	31,967 $2.95 Million
Q3 2018 Nov 15, 2018	BUY	$88.91 - $98.84 $230,988 - $256,786	2,598 Added 8.87%	31,895 $8.63 Million
Q2 2018 Aug 14, 2018	BUY	$89.78 - $106.23 $116,983 - $138,417	1,303 Added 4.65%	29,297 $2.71 Million
Q1 2018 May 14, 2018	SELL	$92.01 - $123.21 $213,463 - $285,847	-2,320 Reduced 7.65%	27,994 $2.65 Million
Q4 2017 Feb 09, 2018	BUY	$89.56 - $98.21 $141,773 - $155,466	1,583 Added 5.51%	30,314 $2.93 Million
Q3 2017 Nov 02, 2017	BUY	$69.85 - $89.22 $2.01 Million - $2.56 Million	28,731	28,731 $2.55 Million

Others Institutions Holding ABBV

# of Institutions

3,853

Shares Held

1.25B

Call Options Held

16.8M

Put Options Held

12.2M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $310B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Smith, Moore & Co., based on Form 13F filings with the SEC.

News

Stay updated on Smith, Moore & Co. with notifications on news.

Account